We love the amazing tech that the team at CellFE is delivering for gene therapy developers. If you haven’t seen their new website, visit them at www.cellfebiotech.com. Better yet, you can meet them in person at this year’s ASGCT in Los Angeles!
We love the amazing tech that the team at CellFE is delivering for gene therapy developers. If you haven’t seen their new website, visit them at www.cellfebiotech.com. Better yet, you can meet them in person at this year’s ASGCT in Los Angeles!
Surrozen is a small biotech developing novel and complex bispecific antibodies that target activation of the WNT pathway to take advantage of its regenerative potential. Although the WNT pathway has been studied for decades, Surrozen — following a partnership with Lonza — is aiming to develop the first therapeutics that intervene in this pathway, and only in diseased tissue.
Over the past 12 months, the average small or emerging Biotech has lost 80-95% of its value, exposing the core of the problem for publicly traded Biotech start-ups.